Released on = April 25, 2007, 4:05 am

Press Release Author = Shushmul Maheshwari

Industry = Healthcare

Press Release Summary = Results of stem cell therapy given to teenagers and young
adults suffering from Type-1 diabetes have instilled a new hope among researchers as
well as patients.

Press Release Body = The results of the stem cell therapy given to teenagers and
young adults suffering from Type-1 diabetes were described to be “very
encouraging” by the two researchers - Richard Burt of Northwestern University
Feinberg School of Medicine, Chicago, and University of Sao Paulo’s Julio
Voltarelli. The patients, on whom the test was done, could discontinue taking
insulin following the successful knock out of their malfunctioning immune systems.
The treatment also reconstructed them from their own stem cells.

Just after giving an injection of stem cells, a large number of patients did not
feel the need to take another insulin injection, as the effect of the first
injection lasted from one to 35 months.

Often, this type of diabetes (Type-1) is diagnosed in young adults or children.
It’s a gene linked disorder which affects approximately1.4 million Americans,
as per the US Centers for Disease Control & Prevention. Even if controlled by taking
insulin injections daily, Type-1 diabetes may result in complications such as heart
disease, high blood pressure, limbs’ amputation, and circulation problems.

A treatment of Type-1 diabetes, which doesn’t require multiple injections of
insulin to be pricked everyday, is sure to offer a hope of a nearly needle free life
for people suffering from this fatal and incapacitating disease.

The multi billion-dollar market of insulin can also be severely impacted by the
successful stem cell treatment – a market wherein a barrage of various
treatment revolutions either have or may continue to remain lackluster. For example,
Exubera – the world’s 1st and perhaps only inhaled insulin product
developed by Pfizer – was once seen as a potential breakthrough drug. Sales of
Exubera however have been particularly disappointing for pharmaceutical giant.

RNCOS report “New Developments in Insulin Delivery System (2006)”
notifies, “Current ambiance in insulin market comprises of strong marketing
plus clinical support in favor of the newly launched products. Drug delivery
products’ sales will likely increase by 100% in the coming five years, since
technologies being researched & developed currently will attain fruition and get
commercialized by that time. Presently, special drug delivery technology’s
market value is US$ 50 Billion per year, i.e. 12.5% of global pharmaceutical
sales.”

This research report “New Developments in Insulin Delivery System
(2006)” helps clients in analyzing the opportunities critical to the growth of
Insulin Delivery Systems in the World. The report addresses some interesting issues
for today’s Global business environment, such as evaluation of current market
trends, discussion about the leading edge technologies, scope of the major insulin
delivery systems all over the world, analysis of various challenges and
opportunities before the industry, etc.

About RNCOS E-Services Pvt Ltd.:

RNCOS, incorporated in the year 2002, is an industry research firm. It has a team of
industry experts who analyze data collected from credible sources. They provide
industry insights and analysis that helps corporations to take timely and accurate
business decision in today\'s globally competitive environment.

For more information visit: http://www.rncos.com/Report/IM040.htm
Current Industry News: http://www.rncos.com/blog


Web Site = http://www.rncos.com

Contact Details = RNCOS E-Services Pvt Ltd.
Shushmul Maheshwari
Head of Business Development
29, 1st Floor, Patparganj Industrial Area, Delhi 92
91-11-4214-1229
info@rncos.com